Rani Therapeutics Holdings, Inc. (RANI): Shareholders' Equity
$33.01M
As of 2025-12-31
$39.23M
As of 2026-06-30
-3.6%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $33.01M | n/m | 2026-03-26, Balance as of period end |
| 2024-12-31 | $1.99M | -84.5% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $12.87M | -65.1% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $36.85M | -22.3% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $47.41M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | -$113.34M | n/a | 2022-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $33.01M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$15.94M | n/m |
| Bio Essence Corp (BIOE) | 2025-12-31 | -$2.07M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.83M | -34.5% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$60.28M | n/m |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$30.15M | n/m |
| Lipocine Inc. (LPCN) | 2025-12-31 | $14.48M | -31.1% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $493.40M | +40.0% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $9.09M | +2.7% |
Compare RANI, NRXP, BIOE, ATXI side by side · Screen every company in Pharmaceutical Preparations ↗